Table 1.
Patients clinical and pathological characteristics at initial diagnosis and at start of Gem/Cape chemotherapy.
| Characteristic | N. ACC patients (%) |
|---|---|
| Median age (range), years | 49 (16–68) |
| <50 | 26/50 (52) |
| ≥50 | 24/50 (48) |
| Sex | |
| Male | 22/50 (44) |
| Female | 28/50 (56) |
| Initial ENSAT tumor stage: | |
| I-II III |
16/50 (32) 9/50 (18) |
| IV | 25/50 (50) |
| Hormone secretion: | |
| No secretion | 24/50 (48) |
| Hormone hypersecretion | 26/50 (52) |
| Glucocorticoids | 22/26 (85) |
| Androgens | 3/26 (11) |
| Aldosterone | 1/26 (4) |
| Pathology | |
| Median Ki67 (range), % | 25 (5–85) |
| Median Weiss score (range) | 6 (3–9) |
| Surgery and resection status: | |
| No surgery | 8/50 (16) |
| R0 | 12/42 (28) |
| RX | 4/42 (10) |
| R1/R2 | 26/42 (62) |
| Number of previous chemotherapy lines 1 |
36/50 (72) |
| ≥2 | 14/50 (28) |
| Time from ACC diagnosis to Gem/Cape start | |
| <19 | 24/47 (51) |
| ≥19 | 23/47 (49) |
| Types of previous chemotherapy lines | |
| Cisplatin-based | 31/50 (62) |
| Anthracyclines-based | 30/50 (60) |
| Streptozotocin/Temozolomide | 4/50 (8) |
| Mitotane concentration during Gem/Cape chemotherapy | |
| <14 mg/L | 29/45 (64) |
| 14–20 mg/L | 16/45 (36) |
| Unknown | 5/50 (18) |
| ECOG performance status at Gem/Cape start | |
| 0 | 19/50 (38) |
| ≥1 | 31/50 (62) |
| Charlson’s Comorbidity Index (CCI) at Gem/Cape start | |
| Score 0–2 | 14/45 (31) |
| Score 3–5 | 6/45 (13) |
| Score ≥ 6 | 25/45 (56) |
| Unknown | 5/50 (10) |
| Metastatic sites at Gem/Cape start | |
| Lung | 38/50 (76) |
| Abdomen/peritoneum | 35/50 (70) |
| Liver | 30/50 (60) |
| Lymphnodes | 17/50 (34) |
| Bone | 2/50 (4) |
| White blood cells (WBC) at Gem/Cape start | |
| <4 × 103/μl | 9/41 (22) |
| 4–10.8 × 103/μl | 27/41 (66) |
| >10.8 × 103/μl | 5/41 (12) |
| Unknown | 9/50 (18) |
| Lactate dehydrogenase (LDH) at Gem/Cape start | |
| Median LDH (range) | 220 (123-1867) |
| ≤225 U/L | 21/42 (50) |
| >225 U/L | 21/42 (50) |
| Unknown | 8/50 (16) |
| Albumin (ALB) at Gem/Cape start | |
| Median ALB (range) ≤3.5 g/dl |
3.5 (2–4.6) 28/50 (56) |
| >3.5 g/dl | 22/50 (44) |
| Body mass index (BMI) | |
| Median ALB (range) | 23.5 (17.8–34.4) |
| ≤23.5 | 26/50 (52) |
| >23.5 | 24/50 (48) |
| Hemoglobin (Hb) at Gem/Cape start | |
| ≤12 g/dl | 25/41 (61) |
| >12 g/dl | 16/41 (39) |
| Unknown | 9/50 (18) |
| Platelet (PLT) at Gem/Cape start | |
| <130 × 103/μl | 1/36 (3) |
| 130 – 400 × 103/μl | 23/36 (64) |
| >400 × 103/μl | 12/36 (33) |
| Unknown | 14/50 (28) |